Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors.

Onco Targets Ther · 2016 · PMC4831599 · PMID 27110122

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

The intent-to-treat analysis demonstrated a nonsignificant trend toward improved median OS with nimotuzumab-RT (12.5 vs 9.47 months).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.